Executive Vice President & President Medsurg
Pierce has navigated a wild 2018, marked by major acquisitions and accusations. In April alone, the 27-year veteran of Boston Scientific helped land the $275 million acquisition of women’s health specialist nVision, a move that will help the company boost early diagnoses of ovarian cancer, the fifth-leading cause of cancer deaths among women. He followed that deal with the blockbuster acquisition of NxThera, the developer of a minimally invasive therapy for patients with symptomatic benign prostatic hyperplasia. Around the same time, Pierce, who also serves as president of Urology and Pelvic Health, unexpectedly became the public face of a scandal involving Boston Scientific’s vaginal mesh products when 60 Minutes broadcast an expose revealing that the company had been using counterfeit Chinese polypropylene to manufacture the devices. In the expose, Pierce denied in a statement that the substance is harmful.